Denmark's Novo Nordisk wants to prove it can transform the diabetes market with a pill.
7 Feb 2018 2:00 PM IST
The daily pill belongs to a blockbuster class of treatments known as GLP-1s that stimulate insulin production.
7 Feb 2018 8:42 AM IST